Daito Pharmaceutical Co.,Ltd. (4577.T)
JPY 2096.0
(0.77%)
JPY 2096.0
(0.77%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 7.55 Billion JPY | -16.5% |
| 2022 | 9.08 Billion JPY | -9.37% |
| 2021 | 9.88 Billion JPY | 8.23% |
| 2020 | 9.03 Billion JPY | 9.53% |
| 2019 | 8.55 Billion JPY | 12.05% |
| 2018 | 7.49 Billion JPY | 5.64% |
| 2017 | 7.14 Billion JPY | 6.54% |
| 2016 | 6.73 Billion JPY | 4.38% |
| 2015 | 6.1 Billion JPY | 7.49% |
| 2014 | 5.87 Billion JPY | 9.36% |
| 2013 | 5.4 Billion JPY | 4.27% |
| 2012 | 5.3 Billion JPY | 4.38% |
| 2011 | 4.88 Billion JPY | 20.3% |
| 2010 | 3.95 Billion JPY | 20.65% |
| 2009 | 3.44 Billion JPY | 9.58% |
| 2008 | 3.12 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 2.45 Billion JPY | 207.4% |
| 2023 Q3 | 1.71 Billion JPY | 41.43% |
| 2023 Q4 | 1.84 Billion JPY | 7.69% |
| 2023 FY | - JPY | -16.5% |
| 2023 Q2 | 1.21 Billion JPY | 10.87% |
| 2023 Q1 | 1.09 Billion JPY | 0.55% |
| 2022 Q3 | 1.32 Billion JPY | 3.75% |
| 2022 Q1 | 1.47 Billion JPY | 59.87% |
| 2022 Q2 | 1.28 Billion JPY | -13.27% |
| 2022 FY | - JPY | -9.37% |
| 2022 Q4 | 1.08 Billion JPY | -18.06% |
| 2021 Q4 | 923.88 Million JPY | -48.32% |
| 2021 Q1 | 2.39 Billion JPY | 274.19% |
| 2021 Q2 | 1.56 Billion JPY | -34.66% |
| 2021 FY | - JPY | 8.23% |
| 2021 Q3 | 1.78 Billion JPY | 14.34% |
| 2020 Q2 | 1.59 Billion JPY | -19.07% |
| 2020 Q3 | 1.86 Billion JPY | 17.42% |
| 2020 Q4 | 639.51 Million JPY | -65.79% |
| 2020 Q1 | 1.96 Billion JPY | 140.71% |
| 2020 FY | - JPY | 9.53% |
| 2019 Q1 | 1.39 Billion JPY | 56.32% |
| 2019 FY | - JPY | 12.05% |
| 2019 Q2 | 1.48 Billion JPY | 6.45% |
| 2019 Q3 | 1.76 Billion JPY | 19.07% |
| 2019 Q4 | 817.23 Million JPY | -53.82% |
| 2018 Q3 | 1.38 Billion JPY | 7.72% |
| 2018 Q2 | 1.28 Billion JPY | 12.47% |
| 2018 Q4 | 893.15 Million JPY | -35.71% |
| 2018 FY | - JPY | 5.64% |
| 2018 Q1 | 1.14 Billion JPY | 15.09% |
| 2017 Q3 | 945.25 Million JPY | -29.39% |
| 2017 Q1 | 979.56 Million JPY | 23.24% |
| 2017 FY | - JPY | 6.54% |
| 2017 Q4 | 996.35 Million JPY | 5.41% |
| 2017 Q2 | 1.33 Billion JPY | 36.67% |
| 2016 Q1 | 975.17 Million JPY | 13.0% |
| 2016 FY | - JPY | 4.38% |
| 2016 Q4 | 794.82 Million JPY | -17.65% |
| 2016 Q3 | 965.16 Million JPY | -14.07% |
| 2016 Q2 | 1.12 Billion JPY | 15.17% |
| 2015 FY | - JPY | 7.49% |
| 2015 Q1 | 1.02 Billion JPY | -7.32% |
| 2015 Q4 | 863.02 Million JPY | -12.1% |
| 2015 Q3 | 981.79 Million JPY | 10.62% |
| 2015 Q2 | 887.57 Million JPY | -13.06% |
| 2014 Q4 | 1.1 Billion JPY | 68.26% |
| 2014 Q1 | 734.59 Million JPY | -14.51% |
| 2014 Q2 | 1.02 Billion JPY | 38.88% |
| 2014 FY | - JPY | 9.36% |
| 2014 Q3 | 654.67 Million JPY | -35.83% |
| 2013 Q4 | 859.25 Million JPY | 53.38% |
| 2013 FY | - JPY | 4.27% |
| 2013 Q3 | 560.22 Million JPY | -36.95% |
| 2013 Q1 | 688.41 Million JPY | -15.57% |
| 2013 Q2 | 888.57 Million JPY | 29.07% |
| 2012 Q3 | 407.15 Million JPY | -45.34% |
| 2012 FY | - JPY | 4.38% |
| 2012 Q2 | 744.91 Million JPY | 9.26% |
| 2012 Q1 | 681.8 Million JPY | -0.27% |
| 2012 Q4 | 815.37 Million JPY | 100.26% |
| 2011 Q1 | 572.67 Million JPY | -45.95% |
| 2011 FY | - JPY | 20.3% |
| 2011 Q2 | 1.01 Billion JPY | 77.0% |
| 2011 Q3 | 460.54 Million JPY | -54.57% |
| 2011 Q4 | 683.64 Million JPY | 48.44% |
| 2010 Q1 | 794.64 Million JPY | 0.0% |
| 2010 Q3 | 1.17 Billion JPY | 4.25% |
| 2010 FY | - JPY | 20.65% |
| 2010 Q4 | 1.05 Billion JPY | -9.58% |
| 2010 Q2 | 1.12 Billion JPY | 41.44% |
| 2009 Q2 | 535.51 Million JPY | 0.0% |
| 2009 FY | - JPY | 9.58% |
| 2008 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | -25.444% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 99.136% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 102.687% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 95.955% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | -1222.832% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 79.187% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 38.428% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 92.675% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | -484.145% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 58.817% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | 15.825% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | -105.804% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | -438.346% |
| Tsumura & Co. | 30.77 Billion JPY | 75.455% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 59.653% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | -43.293% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 78.745% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | -9.75% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 56.893% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | 26.641% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 301.413% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | 1157.843% |
| MedRx Co., Ltd | -884.51 Million JPY | 953.913% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | -36.427% |
| Solasia Pharma K.K. | -635 Million JPY | 1289.449% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 418.165% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | 17.571% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 79.516% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | 1503.15% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 70.776% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | -48.05% |